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Abstract To investigate the role of matrix Gla protein (MGP),
which can bind mineral ions through Q-carboxylated glutamic
acid residues, in vascular calcification, we examined the
expression of MGP in an in vitro calcification model by using
bovine vascular smooth muscle cells (BVSMC). The expression
of MGP mRNA was decreased during BVSMC calcification and
its levels were inversely correlated with the quantities of BVSMC
calcification. MGP mRNA expression was restored to the level
of uncalcified control by inhibiting BVSMC calcification with
bisphosphonates. These data suggest that the expression of MGP
gene is modulated in the development of vascular calcification.
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1. Introduction
Matrix Gla protein (MGP), which was originally isolated
from bovine bone, belongs to a family of extracellular miner-
al-binding proteins called Gla proteins [1^3]. It has been re-
ported subsequently that the MGP gene is expressed in vari-
ous organs including lung, kidney, heart, and cartilage [4,5].
Although Gla proteins bind mineral and mineral ions through
Q-carboxylated glutamic acid residues [2], the functional roles
of MGP even in skeletal tissues remain obscure. However, it
has been recently reported that MGP-de¢cient mice develop
di¡use calci¢cation of arteries and cartilage [6]. Therefore, it is
likely that MGP functions as an inhibitor of calci¢cation in
noncalci¢ed tissues such as arteries and cartilage.
Although vascular calci¢cation was generally regarded as
an unregulated and end-stage process of atherosclerosis, it
has been becoming recognized that it is an active and regu-
lated process similar to osteogenesis [7]. In calci¢ed athero-
sclerotic plaques, the expressions of bone matrix proteins,
including osteopontin and MGP were detected by immuno-
histochemical technique and in situ hybridization [8]. In order
to clarify the molecular mechanism of vascular calci¢cation,
we developed an in vitro calci¢cation system in which di¡use
calci¢cation can be induced by culturing bovine vascular
smooth muscle cells (BVSMC) in the presence of L-glycero-
phosphate (L-GP) [9]. To investigate the role of MGP in vas-
cular calci¢cation, we examined the expression of MGP by
using this in vitro calci¢cation model. In this study, we dem-
onstrated that expression of MGP mRNA is modulated in the
development of BVSMC calci¢cation.
2. Materials and methods
2.1. Reagents
Media, fetal bovine serum (FBS), and sodium pyruvate were pur-
chased from Gibco (Grand Island, NY). L-Glycerophosphate was
obtained from Sigma (St. Louis, MO). Etidronate (EHDP) and
alendronate were kindly provided from Sumitomo Pharmaceuticals
(Osaka, Japan) and Merck Sharp and Dohme Research Laboratories
(West Point, PA), respectively. Unless otherwise mentioned, all other
reagents were obtained from Wako Pure Chemical Industries (Osaka,
Japan).
2.2. Cell culture and in vitro calci¢cation
BVSMC were acquired by an explant method as previously de-
scribed [9]. Brie£y, the tunica media was isolated from bovine aorta.
The tissue was fragmented (1 to 2 mm3) and placed in a 10-cm culture
dish and cultured for several weeks in DMEM containing 4.5 g/l of
glucose supplemented with 15% FBS and 10 mM sodium pyruvate at
37‡C in a humidi¢ed atmosphere containing 5% CO2. Cells that had
migrated from the explants were collected and maintained in the
growing medium. The cells up to passage 8 were used for experiments.
BVSMC calci¢cation was induced as previously described [9]. Brie£y,
BVSMC were cultured in the growing medium. After con£uence, the
cells were seeded in DMEM containing 15% FBS and 10 mM sodium
pyruvate in the presence of 10 mM L-glycerophosphate. The medium
was replaced with fresh medium every 2 days. In the time-course
experiments, the beginning day of culture in calci¢cation medium
was de¢ned as day 0.
2.3. Quanti¢cation of calcium deposition
The cells were decalci¢ed with 0.6 N HCl for 24 h. The calcium
content of HCl supernatant was determined colorimetrically by o-cre-
solphthalein complexone method (Calcium C-test Wako; Wako Pure
Chemical Industries, Osaka, Japan) [10]. After decalci¢cation, the cells
were washed three times with phosphate-bu¡ered saline (PBS) and
solubilized with 0.1 N NaOH/0.1% sodium dodecyl sulfate (SDS).
The protein content was measured with a BCA protein assay kit
(Pierce, Rockford, IL). The calcium content of cell layer was normal-
ized by protein content.
2.4. Preparation of cDNA probes
Bovine MGP cDNA probe containing a 232-base pair fragment
(corresponding to 54 to 285 in the coding region) was obtained by
reverse transcription of an mRNA from BVSMC, followed by polym-
erase chain reaction and subcloning into TA cloning vector (Invitro-
gen, Carlsbad, CA). Sequences of the obtained cDNA were con¢rmed
by dideoxy sequencing method.
2.5. RNA isolation and Northern blot analysis condition
Total RNA was isolated from BVSMC by extraction with acid
guanidium thiocyanate-phenol-chloroform. Twenty micrograms of
total RNA were electrophoresed on 1% agarose gels containing
formaldehyde and transferred to a nylon ¢lter (Hybond N, Amer-
sham, Buckinghamshire, UK). Blots were prehybridized at 37‡C
for 24 h in a bu¡er containing 50% formamide, 3USSC (1USSC,
0.15 M NaCl and 15 mM sodium citrate, pH 7.4), 50 mmol/l
Tris-HCl (pH 7.5), 0.1% SDS, 20 Wg/ml denatured salmon sperm
DNA, and 1UDenhardt’s solution and then hybridized at 37‡C for
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48 h with cDNA probe for bovine MGP that was labeled with
[K-32P]dCTP (3000 Ci/ml; New England Nuclear, Boston, MA)
by use of a random priming method (Megaprime cDNA labeling
system, Amersham, Buckinghamshire, England). Blots were washed
and autoradiographed with X-ray ¢lm at 370‡C. The amounts of
RNA were quanti¢ed by densitometric scanning and normalized
by comparison with glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) [11].
3. Results
As previously described, 10 mM L-GP increased calcium
deposition in a time-dependent manner (Fig. 1a). We exam-
ined the e¡ect of calci¢cation on MGP mRNA expression by
Northern blot analysis. As shown in Fig. 1b, MGP mRNA
expression was depressed in the development of BVSMC
calci¢cation in a time-dependent manner and on day 6
the level of MGP mRNA was reached to 8.3% of that of
uncalci¢ed control. We next examined the relationship
between the contents of calcium deposition and the levels of
MGP mRNA. Calcium deposition was dose-dependently in-
creased by the addition of L-GP (Fig. 2a). On the other hand,
the levels of MGP mRNA were decreased in accordance with
the increase of calcium deposition and at 10 mM L-GP the
expression was maximally depressed to 47.6% of uncalci¢ed
control (Fig. 2b). These results suggest that the expression of
MGP gene is inversely correlated with the degree of BVSMC
calci¢cation.
Finally, we examined the e¡ects of bisphosphonates such as
etidronate (EHDP) and alendronate on the expression of
MGP mRNA. Both of EHDP and alendronate dose-depend-
ently inhibited BVSMC calci¢cation (Figs. 3a and 4b, respec-
tively). In the presence of EHDP or alendronate, MGP
mRNA expression was restored to the level of uncalci¢ed
control (Figs. 3b and 4b, respectively). These data further
con¢rm that the expression of MGP gene is modulated in
the development of BVSMC calci¢cation.
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Fig. 1. Time courses of BVSMC calci¢cation (a) and expression of
MGP mRNA (b). The cells were cultured as described in Section 2.
L-GP (+) and (3) indicate the presence and absence of L-glycero-
phosphate, respectively. Calci¢ed group is indicated by closed
square and uncalci¢ed control is indicated by open circle. a: The
calcium content was measured at the indicated times by o-cresolph-
thalein complexone method, normalized by cellular protein content,
and is presented as mean þ S.E.M. The di¡erences compared with
uncalci¢ed control at each time point were statistically signi¢cant
(*P6 0.05, Fisher’s PLSD). b: Twenty micrograms of total RNA
from BVSMC at the indicated times were electrophoresed, blotted,
and probed with cDNA of bovine MGP. GAPDH, glyceraldehyde-
3-phosphate dehydrogenase. Upper panel, autoradiograph of North-
ern analysis of MGP. Lower panel, densitometric analysis of the
autoradiograms was performed and the results are presented as the
ratio of MGP to GAPDH.
Fig. 2. Dose-dependent e¡ects of L-GP on BVSMC calci¢cation (a)
and expression of MGP mRNA (b). The cells were cultured for
4 days as described in Section 2. a: The calcium content was meas-
ured by o-cresolphthalein complexone method, normalized by cellu-
lar protein content, and is presented as mean þ S.E.M. The di¡eren-
ces compared with uncalci¢ed control were statistically signi¢cant
(*P6 0.05, Fisher’s PLSD). b: Twenty micrograms of total RNA
from BVSMC were electrophoresed, blotted, and probed with
cDNA of bovine MGP. GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase. Upper panel, autoradiograph of Northern analysis of
MGP. Lower panel, densitometric analysis of the autoradiograms
was performed and the results are presented as the ratio of MGP to
GAPDH.
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4. Discussion
We reported here for the ¢rst time the inverse relationship
between vascular calci¢cation and expression of MGP gene by
using an in vitro model of vascular calci¢cation. Our results
indicate that vascular calci¢cation may modulate the expres-
sion of MGP gene. MGP is a vitamin K-dependent protein
and belongs to a family of extracellular mineral-binding pro-
teins called Gla proteins [1^3]. Gla residues have high a⁄nity
for calcium and phosphate ions, and hydroxyapatite crystals
[2]. Unlike bone Gla protein, which may be involved in min-
eralization of skeletal tissues, the function of MGP remains
unknown. MGP was ¢rst isolated from bovine bone, but is
now known to be synthesized in various tissues including vas-
cular smooth muscle cells [4,12]. Furthermore, Shanahan et al.
reported that MGP and osteopontin were highly expressed in
human atherosclerotic plaques, suggesting that bone matrix
proteins, such as MGP, have an important role in the patho-
genesis of atherosclerotic plaques [8]. More recently, it is re-
ported that MGP-de¢cient mice developed arterial calci¢ca-
tion and died within 2 months by blood vessel rupture [6].
These results strongly suggest that MGP may function as an
inhibitor of arterial walls. However, whether MGP itself pre-
vents vascular calci¢cation in this model remains to be clari-
¢ed.
Vascular calci¢cation is often detected in advanced athero-
sclerotic lesions and was generally regarded as an unregulated
and end-stage process of atherosclerosis. However, it has been
recently becoming recognized that it is an active and regulated
process similar to osteogenesis, since bone matrix proteins,
such as osteopontin and MGP are expressed in atherosclerotic
lesions [8]. Moreover, vascular calci¢cation is also often asso-
ciated with cartilaginous metaplasia in which MGP seems to
be abundantly expressed [13]. Therefore, it is likely that MGP
may modulate the osteogenic and/or chondrocytic di¡erentia-
tion of VSMC in the development of atherosclerotic lesions.
Additionally, it is noteworthy that MGP-de¢cient mice have
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Fig. 3. Dose-dependent e¡ects of etidronate on BVSMC calci¢cation
(a) and expression of MGP mRNA (b). The cells were cultured for
4 days as described in Section 2 in the presence of the indicated
concentrations of etidronate (EHDP). a: The calcium content was
measured by o-cresolphthalein complexone method, normalized by
cellular protein content, and is presented as mean þ S.E.M. The dif-
ferences compared with calci¢ed control were statistically signi¢cant
(*P6 0.05, Fisher’s PLSD). b: Twenty micrograms of total RNA
from BVSMC were electrophoresed, blotted, and probed with
cDNA of bovine MGP. GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase. Upper panel, autoradiograph of Northern analysis of
MGP. Lower panel, densitometric analysis of the autoradiograms
was performed and the results are presented as the ratio of MGP to
GAPDH.
Fig. 4. Dose-dependent e¡ects of alendronate on BVSMC calci¢ca-
tion (a) and expression of MGP mRNA (b). The cells were cultured
for 4 days as described in Section 2 in the presence of the indicated
concentrations of alendronate. a: The calcium content was meas-
ured by o-cresolphthalein complexone method, normalized by cellu-
lar protein content, and is presented as mean þ S.E.M. The di¡eren-
ces compared with calci¢ed control were statistically signi¢cant
(*P6 0.05, Fisher’s PLSD). b: Twenty micrograms of total RNA
from BVSMC were electrophoresed, blotted, and probed with
cDNA of bovine MGP. GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase. Upper panel, autoradiograph of Northern analysis of
MGP. Lower panel, densitometric analysis of the autoradiograms
was performed and the results are presented as the ratio of MGP to
GAPDH.
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arterial calci¢cation but no evidence of atherosclerotic plaques
[6], suggesting that vascular calci¢cation may be controlled by
the genes including MGP, which are di¡erent from the genes
regulating the formation of atherosclerotic lesions.
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